Outcome of COVID-19 Cases Admitted to Hospital and ICU With Positive Tuberculin Test: Can Previous BCG Alter the Prognosis?
试验速览
- 阶段
- 不适用
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Pneumonia severity index
研究概览
简要总结
There is no evidence that the Bacille Calmette-Guérin vaccine (BCG) protects people against infection with COVID-19 virus. Two clinical trials addressing this question are underway, and WHO will evaluate the evidence when it is available. In the absence of evidence, WHO does not recommend BCG vaccination for the prevention of COVID-19. WHO continues to recommend neonatal BCG vaccination in countries or settings with a high incidence of tuberculosis. There is experimental evidence from both animal and human studies that the BCG vaccine has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance is unknown
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 12 Years 至 80 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •COVID-19 positive cases admitted to hospitals in Upper Egypt
排除标准
- 未提供
结局指标
主要结局
Pneumonia severity index
时间窗: 2 weeks
severity of COVID-19 pneumonia
Need for ICU admission
时间窗: 2 weeks
severe pneumonia indicating invasive or non invasive mechanical ventilation
次要结局
- COVID -19 test conversion(2 weeks)
- Mortality(2 weeks)
研究者
Aliae AR Mohamed Hussein
Professor of Pulmonology
Assiut University